IMM ONC 01
Alternative Names: IMM 20320 -; IMM-ONC-01Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Immunome
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Interleukin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 23 May 2023 Pharmacodynamics data from a preclinical trial in Solid tumours released by Immunome
- 14 Nov 2022 Immunome plans to file IND application for Cancer (Parenteral) in mid-2023